Allworth Financial’s Ligand Pharmaceuticals LGND Stock Holding History

Allworth Financial’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$64.2K	Sell	203 -1	-0.5%	-$236	﹤0.01%	2270
2026 Q1	$40.7K	Sell	204 -347	-63%	-$68.7K	﹤0.01%	2478
2025 Q4	$104K	Buy	551 +8	+1%	+$1.54K	﹤0.01%	1727
2025 Q3	$96.2K	Buy	543 +2	+0.4%	+$297	﹤0.01%	1709
2025 Q2	$61.5K	Buy	541 +4	+0.7%	+$428	﹤0.01%	1831
2025 Q1	$58.3K	Buy	537 +21	+4%	+$2.38K	﹤0.01%	1482
2024 Q4	$59.8K	Buy	516 +1	+0.2%	+$113	﹤0.01%	1494
2024 Q3	$51.5K	Hold	515	–	–	﹤0.01%	1397
2024 Q2	$51.4K	Buy	515 +360	+232%	+$28.6K	﹤0.01%	1376
2024 Q1	$11.3K	Hold	155	–	–	﹤0.01%	2051
2023 Q4	$11.1K	Sell	155 -25	-14%	-$1.48K	﹤0.01%	1944
2023 Q3	$10.8K	Buy	180 +31	+21%	+$2.04K	﹤0.01%	1813
2023 Q2	$10.7K	Hold	149	–	–	﹤0.01%	1838
2023 Q1	$11K	Hold	149	–	–	﹤0.01%	1760
2022 Q4	$9.95K	Sell	149 -98	-40%	-$6.37K	﹤0.01%	1688
2022 Q3	$13K	Buy	+247	New	+$14.5K	﹤0.01%	1491

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allworth Financial's LGND Position: Q2 2026 in Review

Allworth Financial reduced its Ligand Pharmaceuticals (LGND) stake by 0.49% in Q2 2026, selling an estimated $236 and leaving 203 shares worth $64.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2270.

Allworth Financial first reported a position in LGND in Q3 2022 and has held it in 16 quarters since. The position peaked at $104K in Q4 2025. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Allworth Financial held 203 shares of Ligand Pharmaceuticals worth $64.2K as of Q2 2026.
Allworth Financial sold 1 Ligand Pharmaceuticals share in Q2 2026, an estimated $236.
Ligand Pharmaceuticals made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #2270 holding.
Allworth Financial first reported a position in Ligand Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
Allworth Financial's Ligand Pharmaceuticals position peaked at $104K in Q4 2025.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.